On November 30, 2024, the highly anticipated 2024 China BioMed Innovation and Investment Conference (CBIIC) was grandly held in Guangzhou. With the continuous advancement of medical technologies and the growing demand for health services, the development of innovative medical devices has become a key focus in the pharmaceutical industry.

As a major event in China’s pharmaceutical industry, CBIIC has long been committed to promoting the integrated development of pharmaceutical innovation and investment. Innovative medical devices, as an important part of the pharmaceutical industry, possess vast market potential and growth opportunities. The hosting of this Innovative Medical Device Roadshow is precisely aimed at meeting the industry’s development needs, providing a platform for communication and collaboration between innovative medical device companies and investors, and exploring the development trends and investment opportunities in innovative medical devices.

The roadshow brought together many cutting-edge innovation projects and industry elites, attracting the participation of innovative medical device companies from across the country. The showcased projects spanned multiple fields, including medical imaging, biotechnology, in-vitro diagnostics, and organ medicine. Each project featured unique characteristics in terms of technological innovation, market application, and development plans, offering diversified solutions and development directions for the advancement of the medical industry.

The roadshow was hosted by Mr. Luo Jian, Senior Director of Business Development for BD Greater China, and Ms. Delphine Qiu, Principal of Eight Roads. 

Mr. Luo Jian, Senior Director of Business Development for BD Greater China

Ms. Delphine Qiu, Principal of Eight Roads

Project Highlights

Quantitative Rapid Test for At-home Screening and Management of Personal Healthcare

Presenter: Liu Wengang, CEO, Cimple Biotechnology Limited

Cimple Biotechnology introduced a quantitative rapid test kit for home self-health screening and management, which includes a microfluidic chip and a mobile app. The app analyzes biomarker concentrations, while the results can also be read visually. This platform technology is applicable for testing samples such as skin tissue fluid, blood, and urine, covering chronic diseases, reproductive health, and early cancer screening.

Ultrasonic Brain Imaging

Presenter: Shu Yaogen, General Manager, Wenzhou Baiouji Technology Co., Ltd.

Ultrasound brain imaging uses reflective and transmitted wave information from transcranial ultrasound to present brain structural information in a three-dimensional form, with submillimeter resolution at the single-cell level. Compared to traditional MRI, ultrasound brain imaging does not require superconductivity or low temperatures, is less demanding on space, and significantly reduces costs. This technology is suitable for use in disaster relief, ambulances, and special populations such as pregnant women. It is completely original and not limited by foreign patents, with significant potential for development in the next five years.

iCubate Ultra-Multiplex PCR Technology Platform — FDA-Certified Key Technology for Decoding Immune System Data

Presenter: Dong Qingquan, CBO, Guangzhou Fangyu Biotech Co., Ltd.

 The iCubate Multiplex PCR technology platform has advanced immunomics sequencing and has important applications in precision medicine. Unlike traditional multiplex PCR, the iCubate platform solves issues related to incompatible amplification conditions, background amplification, and primer dimer formation. With fifteen years of accumulated patented technologies (arm-PCR, dam-PCR), it provides unbiased, quantitative, and high signal-to-noise ratio amplification, reducing noise interference and ensuring the accuracy of data. The simplified library construction process makes the experiment more convenient and is key in decoding and analyzing immunological data for applications in precision medicine.

Global Innovation, Made in China - New Recombinant Humanized Collagen Biomaterial the Path to Industrialization

Presenter: Tang Menghua, Director, Vice General Manager and Board Secretary, Shanxi Jinbo Biopharmaceutical Co.,Ltd.

Wei Yimei recombinant Type III humanized collagen freeze-dried fibers, developed independently in China, are the first medical devices made from novel biological materials—recombinant humanized collagen. This product lays a solid foundation for the clinical application and industrial transformation of related materials. Wei Yimei has the following characteristics: its amino acid sequence repeats the specific functional areas of human collagen, ensuring good biocompatibility; its functional regions form a flexible triple-helix structure, with structural data already included in international protein structure databases; and it has higher cell adhesion compared to human Type I and Type III collagen, forming a network fiber structure with excellent repair properties.

Laso Biotech－China’s Pioneer Microarrays Provider

Presenter: Chen Zhuo, CFO, LASO Biotech, Beijing Co., Ltd. 

LASO Biotech is the first company in China to achieve the independent R&D, production, and commercialization of high-density solid-phase gene chips. The company offers an integrated solid-phase gene chip solution that includes customizable chips, scanning equipment, reagents, professional algorithms, and supporting software. To date, the company has obtained 13 invention patents, 5 utility model patents, 3 design patents, and 1 medical device registration certificate, making it the company with the most comprehensive intellectual property layout and self-controlled core technologies in the high-density chip field under Chinese law. The domestically developed high-density gene chip platform by Lasso Biotech has vast application potential and growth opportunities in various sectors, including agricultural molecular breeding, consumer healthcare, human medicine, and scientific research.

Novel Bioactive Materials Based on Microsphere Delivery System Technology in Wound Repair and Skin Regeneration

Presenter: Guo Xiaofeng, Research Director, Guangzhou Dongyuan Oriplamacy Technology Co.

Dongyuan Oriplamacy has developed an innovative drug, AVBER, utilizing the “natural plant active ingredient light quantum condensation synthesis technology” and the “microsphere drug delivery system technology.” AVBER, derived from the aloe plant, can be applied topically for rapid transdermal absorption, effectively promoting the full regeneration and repair of wounds and their associated structures such as hair follicles and sweat glands, with no scar formation. Its safety and efficacy have been confirmed in multiple animal models and real-world observational studies. Compared to expensive growth factor-based drugs, AVBER is more cost-effective and offers better therapeutic outcomes. Therefore, AVBER holds significant technical advantages and clinical value in the field of wound repair.

Singularity Medical - Organ Medicine Pioneer

Presenter: Fang Xiaomin, General Manager, Singularity Medical Technology (Guangzhou) Co., Ltd.

Singularity Medical is the world’s first innovative biopharmaceutical technology company engaged in “organ medicine” research and industrial development. In the field of organ transplantation, it invented the dry perfusion machine, which achieves non-ischemic transplantation by maintaining organ blood flow uninterrupted. In research, Singularity Medical has developed a model for primary disease research by removing organs with liver tumors and performing drug testing, and has partnered with leading CROs and pharmaceutical companies globally. In the therapeutic field, the company invented kidney isolation protection and liver cancer isolation treatment technologies, using interventional techniques to isolate the blood flow of affected organs for protection treatment. Additionally, it has achieved a breakthrough in reviving a pig heart after 50 minutes of cardiac arrest, gaining continuous support from national innovation projects.

Activated Coral Bone Grafts - A Natural Alternative to Human Bone and Grafts of Bovine Origin

Presenter: Zheng Xuan, Clinical Director, Gu Zhi Yuan (Guangzhou) Medical Technology Co.

Cartilage regeneration is one of the most significant unmet needs in orthopedics. So far, no effective solutions for cartilage damage have been developed. Gu Zhi Yuan Medical is the Chinese subsidiary of the Israeli company Corebone. The company’s core technology involves artificial coral cultivation, and the cultured coral has received CE certification, making it the only artificial cultivated coral globally that can be used in the medical field. Since 2018, the company has obtained multiple patents in China. The company focuses on the development of orthopedic repair materials, including dental and orthopedic products based on active coral bone grafts. Compared to existing bone graft products, the active coral grafts have no risk of disease transmission or rejection, no ethical concerns, excellent absorbability, and are competitively priced.

ML-Diabetes: A Machine Learning-Based Precision Tool for Comprehensive Diabetes Care

Presenter: Zou Xiantong, Assistant Professor of Peking University

ML-Diabetes is a machine learning-based tool designed to assist with diabetes management across its full course, aiming to provide personalized treatment plans for diabetes patients using artificial intelligence. As diabetes prevalence rises, particularly in China, traditional management models are insufficient to meet personalized needs. ML-Diabetes uses machine learning technology to develop various management tools, such as the Diabetes Progression Prediction Platform (ML-PR), Diabetes Cluster Typing Platform, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Prediction Platform (ML-PANPPAR), Urinary Protein Progression Prediction Platform (ML-ACR), and Cardiovascular Disease Prediction Platform (ML-CVD). These platforms enable accurate prediction and personalized management of diabetes at different stages.

With AI and Semiconductors as Wings, Life Science and Technology Can Benefit All Living Beings

Presenter: Theresa Huang, Operations Director, GeneSense Hong Kong Limited 

GeneSense as a pioneer in cross-industry integration, effectively combines cutting-edge AI technology with multi-omics detection in biology, leveraging semiconductor technology to create an innovative "one-stop pathway" that delivers samples directly to reports. This approach makes healthcare services more accessible and personalized. The company’s unique solutions act as a “key” to unlocking human health data, promising to bring unprecedented transformation to the healthcare industry. 

This Innovative Medical Device Roadshow not only provided a platform for showcasing and financing opportunities for innovative medical device companies, but also offered investors high-quality investment projects. Additionally, the event fostered technological exchanges and collaborations within the industry, driving the innovative development of medical devices. Many participants expressed that, through this event, they gained a clearer understanding of the development prospects of innovative medical devices, laying a foundation for future investments and collaborations.